Ian E. Krop

Also affiliated with Yale University, Smilow Cancer Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.2Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Papers

Driven by 26 papers — median percentile 82. Top paper: “Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer”.

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

Breast Cancer Research(2020)10.1186/s13058-020-01354-y

N/A

3.0DataRank · unranked

148 citations

Cristina Saura, Romualdo Barroso‐Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo +18 more

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Nature Cancer(2022)10.1038/s43018-022-00491-x

Top 9%

2.4DataRank

Top 9%114 citations

Toshinori Hinoue, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro, Tomás Pascual +53 more

Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth

Nature Biomedical Engineering(2022)10.1038/s41551-022-00855-9

N/A

2.2DataRank · unranked

83 citations

Erica Nguyen, Jin H. Bae, Timothy Blewett, Justin Rhoades, Sarah C. Reed +15 more

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Nature Communications(2021)10.1038/s41467-021-25769-z

N/A

1.8DataRank · unranked

48 citations

Jennifer L. Guerriero, Romualdo Barroso‐Sousa, Tianyu Li, Tess A. O’Meara, Anita Giobbie‐Hurder +24 more

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

Nature Medicine(2023)10.1038/s41591-023-02392-7

N/A

1.6DataRank · unranked

66 citations

Albert E. Kim, Anita Giobbie‐Hurder, Eudocia Q. Lee, Nancy U. Lin, Beth Overmoyer +28 more

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005119

N/A

1.2DataRank · unranked

39 citations

Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Gerburg M. Wulf, Edward T. Richardson +10 more

Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2305

N/A

0.918DataRank · unranked

28 citations

Tianyu Li, Albert Grinshpun, Tim H. H. Coorens, Douglas Russo, Leilani Anderson +16 more

Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer

Future Oncology(2021)10.2217/fon-2021-0753

N/A

0.901DataRank · unranked

30 citations

Karla V. Ballman, Linda McCall, Anuhya Kommalapati, Tyler Zemla, Anna Weiss +12 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772

Top 27%

0.742DataRank

Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

Neuro-Oncology(2023)10.1093/neuonc/noad236

N/A

0.323DataRank · unranked

6 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

MAESTRO affords ‘breadth and depth’ for mutation testing

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.01.22.427323

N/A

0.314DataRank · unranked

5 citations

Erica Nguyen, Jin H. Bae, Justin Rhoades, Sarah C. Reed, Douglas Shea +15 more

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.25.554868

N/A

0DataRank · unranked

0 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.tps632

N/A

0DataRank · unranked

2 citations

Kathryn J. Ruddy, Naim U. Rashid, Jasmine Sukumar, Sharon H. Giordano, Gaorav P. Gupta +10 more

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

UNC Libraries(2024)10.17615/m9ck-zv98

N/A

0DataRank · unranked

0 citations

Jonathan C. Silverstein, AURORA US Network, Melina E Sanders, P.W. Laird, C.M. Perou +53 more

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.02.008

N/A

0DataRank · unranked

157 citations

Ofir Cohen, Bose Kochupurakkal, D. Kim, Connor E. Dunn, Jorge Buendia +20 more

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

Clinical Breast Cancer(2025)10.1016/j.clbc.2025.05.009

N/A

0DataRank · unranked

0 citations

Xiangying Chu, Tarah J. Ballinger, Nisha Unni, Sarah Sinclair, Robert Wesolowski +9 more

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1014

N/A

0DataRank · unranked

356 citations

Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi +11 more

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3685

N/A

0DataRank · unranked

60 citations

Mellissa J. Nixon, Paula I. González-Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell +21 more

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

UNC Libraries(2020)10.17615/6adk-r027

N/A

0DataRank · unranked

0 citations

Carey K. Anders, Charles M. Perou, Ian E. Krop, Constance Cirrincione, Brandelyn N. Pitcher +13 more

A Phase II Study of Sagopilone (ZK 219477; ZK-EPO) in Patients With Breast Cancer and Brain Metastases

UNC Libraries(2020)10.17615/arc0-j974

N/A

0DataRank · unranked

0 citations

Lixian Sun, Eric P. Winer, Rachel A. Freedman, Elizabeth Bullitt, Nancy U. Lin +6 more

Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

UNC Libraries(2020)10.17615/e33z-ag80

N/A

0DataRank · unranked

0 citations

Harold J. Burstein, Lisa A. Carey, Antonio C. Wolff, Sara M. Tolaney, P. Kelly Marcom +15 more

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer

JCI Insight(2021)10.1172/jci.insight.147617

N/A

0DataRank · unranked

42 citations

Shayna Stein, Otto Metzger, Jennifer Eng, Natalie L. Kingston, Nicholas W. Harper +18 more

FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

npj Breast Cancer(2021)10.1038/s41523-021-00258-0

N/A

0DataRank · unranked

24 citations

Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, José F. Olivares-Quintero +25 more

Multiplatform Analysis of Primary and Metastatic Breast Tumors from the AURORA US Network identifies microenvironment and epigenetics drivers of metastasis

Research Square(2022)10.21203/rs.3.rs-1221704/v1

N/A

0DataRank · unranked

2 citations

Susana García‐Recio, Toshinori Hinoue4, Gregory Wheeler, Benjamin Kelly, Ana C. Garrido-Castro +49 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of Oncology(2023)10.1016/j.annonc.2023.08.004

N/A

0DataRank · unranked

58 citations

Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature Communications(2023)10.1038/s41467-023-42635-2

N/A

0DataRank · unranked

17 citations

Aranzazu Fernández-Martínez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker +17 more

Ian E. Krop

Indexed papers

Top data-sharing exemplar

Papers